한글목차

위체류 약물전달 시스템(GRDDS) 아웃소싱 동향 및 전망

고밀도 시스템, 확장형 약물전달 시스템, 생체 접착 약물전달 시스템, 부유식 약물전달 시스템 시장에서 기회가 있으며, 세계 위체류 약물전달 시스템(GRDDS) 아웃소싱 시장의 미래는 유망합니다. 세계 위체류 약물전달 시스템 아웃소싱 시장은 2024년부터 2030년까지 연평균 6.7%의 성장률을 보일 것으로 예상됩니다. 이 시장의 주요 촉진요인은 환자 중심 솔루션에 대한 관심 증가, 아웃소싱 수요 증가, 국소 약물전달에 대한 관심 증가, 연구 개발 프로그램에 대한 투자 증가입니다.

• Lucintel의 예측에 따르면, 제형별로는 캡슐이 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.
• 시장 유형별로는 부유식 약물전달시스템이 가장 높은 성장세를 보일 것으로 예상됩니다.
• 지역별로 보면 북미는 정교한 제약 부문, 강력한 R&D 역량, 강력한 시장 수요, 확립된 의료 시스템으로 인해 예측 기간 동안 가장 높은 성장률을 보일 것으로 예상됩니다.

위체류 약물전달 시스템(GRDDS) 아웃소싱 시장의 전략적 성장 기회

제약사들이 만성질환 및 복합질환을 위한 첨단 약물전달시스템 개발에 점점 더 집중하고 있는 가운데, 위체류 약물전달 시스템(GRDDS) 아웃소싱 시장은 큰 전략적 성장 기회를 제공하고 있습니다. 비용 절감, 제품 개발 가속화, 전문 지식 활용 등 아웃소싱의 장점은 시장 성장에 유리한 환경을 조성하고 있습니다. 이러한 기회를 통해 CMO는 역량을 확장하고, 서비스 제공을 강화하며, 새로운 시장을 개척할 수 있습니다.

• 아웃소싱 파트너십 확대 : 제약사들은 GRDDS 전문 CMO와의 제휴를 늘려 생산 공정을 간소화하고 효율성을 높이며 첨단 기술에 접근하기 위해 노력하고 있습니다.
• 만성질환 관리에 대한 수요 증가 : 당뇨병, 고혈압, 위장장애와 같은 만성질환의 증가는 장기적인 약물 순응도를 개선하기 위한 특수 GRDDS 제제를 개발할 수 있는 기회를 가져옵니다.
• 지리적 확장 : 헬스케어 수요가 증가하는 신흥 시장으로 아웃소싱 사업을 확장함으로써 CMO는 새로운 지역에서 시장 점유율을 확보할 수 있는 큰 기회를 얻을 수 있습니다.
• 개인화 의료 : 환자별 맞춤형 제제 개발 추세는 GRDDS 기업들에게 개별 치료 요구에 맞는 솔루션을 제공할 수 있는 큰 기회가 될 것입니다.
• 첨단 기술 통합 : GRDDS의 아웃소싱 프로세스에 AI, 데이터 분석 등 첨단 기술을 통합하여 제품 개발 최적화, 비용 절감, 품질 관리를 향상시킬 수 있습니다.

특수 약물전달시스템에 대한 수요, 만성질환 관리의 발전, 맞춤형 의료에 대한 수요 증가로 인해 위체류 약물전달 시스템(GRDDS) 아웃소싱 시장의 전략적 성장 기회는 풍부하며, 이를 이끄는 원동력은 다양합니다. CMO는 아웃소싱 파트너십 확대, 지리적 범위 확대, 차세대 기술 통합에 집중함으로써 이러한 기회를 활용할 수 있습니다. 시장이 성장함에 따라 이러한 요인들이 위체류 약물전달 시스템(GRDDS) 아웃소싱의 미래를 형성하고 새로운 성장의 길을 열어줄 것으로 보입니다.

위체류 약물전달 시스템(GRDDS) 아웃소싱 시장 활성화 요인 및 과제

위체류 약물전달 시스템(GRDDS) 아웃소싱 시장은 첨단 약물전달 기술에 대한 수요 증가, 만성질환 관리에 대한 의료 수요 증가, 비용 효율적인 의약품 제조 추세 등 다양한 촉진요인에 의해 영향을 받고 있습니다. 그러나 복잡한 규제, 높은 제조 비용, 기술적 한계 등 여러 가지 도전에 직면해 있습니다. 경쟁에서 살아남고 성장 기회를 활용하고자 하는 기업들은 이러한 촉진요인과 도전 과제를 이해하는 것이 필수적입니다.

시장 촉진요인

• 만성질환 치료에 대한 수요 증가 : 당뇨병, 고혈압 등 만성질환의 증가로 인해 약물 방출 조절 및 지속성에 대한 요구가 증가하면서 GRDDS에 대한 수요가 증가하고 있습니다.
• 비용 절감을 위한 아웃소싱 : 제약회사들은 제조 비용 절감, 업무 유연성 향상, 시장 출시 시간 단축을 위해 GRDDS 제조 아웃소싱을 점점 더 많이 추진하고 있습니다.
• 제형 기술의 발전 : 생체 접착 시스템, 방출 제어 메커니즘 등 약물전달 기술의 끊임없는 발전이 GRDDS 애플리케이션의 성장을 뒷받침하고 있습니다.
• 복약 순응도 강조 : GRDDS는 환자의 장기적인 치료 순응도를 향상시키는 데 중요한 역할을 하고 있으며, 만성질환 관리에서 GRDDS의 채택을 촉진하고 있습니다.
• 보다 안전하고 효과적인 치료법을 위한 규제 강화 : 약물전달 시스템에 대한 규제 요건이 강화됨에 따라 기술 혁신이 촉진되고, 신뢰성과 컴플라이언스를 갖춘 GRDDS 솔루션에 대한 수요가 증가하고 있습니다.

시장의 과제

• 높은 개발 및 제조 비용 : GRDDS 제제의 개발 및 제조가 복잡하기 때문에 특히 중소기업의 경우 초기 투자 및 운영 비용이 높을 수 있습니다.
• 규제 장애물 : 복잡하고 지역별로 다른 규제 요건을 극복하는 것은 시장 진입을 지연시키고 개발 비용을 증가시킬 수 있습니다.
• 기술의 복잡성 : GRDDS의 설계 및 제조에는 고도의 기술이 필요하기 때문에 전문 지식이 필요하며, 경험이 부족한 기업의 경우 시장 진입이 제한될 수 있습니다.

위체류 약물전달 시스템(GRDDS) 아웃소싱 시장은 만성질환 치료에 대한 수요 증가, 기술 발전, 아웃소싱을 통한 비용 절감 효과 등의 요인에 의해 주도되고 있습니다. 그러나 높은 개발 비용, 규제 복잡성, 기술적 장벽 등 여러 가지 도전 과제에 직면해 있습니다. 이러한 도전과제를 극복하고 시장 촉진요인과 과제를 활용한다면, 위체류 약물전달 시스템(GRDDS) 아웃소싱 분야의 기업들은 빠르게 진화하는 시장에서 지속적인 성장과 성공을 거둘 수 있습니다.

목차

제1장 주요 요약

제2장 세계의 위체류 약물전달 시스템(GRDDS) 아웃소싱 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계 성장 촉진요인과 과제

제3장 2018년부터 2030년까지 시장 동향과 예측 분석

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 위체류 약물전달 시스템(GRDDS) 아웃소싱 시장 동향(2018-2023)과 예측(2024-2030)
• 유형별 : 세계의 위체류 약물전달 시스템(GRDDS) 아웃소싱 시장
  • 고밀도 시스템
  • 확장 가능한 약물전달 시스템
  • 생체 접착성 약물전달 시스템
  • 부유성 약물전달 시스템
  • 기타
• 투여 형태별 : 세계의 위체류 약물전달 시스템(GRDDS) 아웃소싱 시장
  • 태블릿
  • 액체
  • 마이크로스피어
  • 캡슐
  • 기타
• 유통 채널별 : 세계의 위체류 약물전달 시스템(GRDDS) 아웃소싱 시장
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제4장 2018년부터 2030년까지 지역별 시장 동향과 예측 분석

• 지역별 위체류 약물전달 시스템(GRDDS) 아웃소싱 시장
• 북미의 위체류 약물전달 시스템(GRDDS) 아웃소싱 시장
• 유럽의 위체류 약물전달 시스템(GRDDS) 아웃소싱 시장
• 아시아태평양의 위체류 약물전달 시스템(GRDDS) 아웃소싱 시장
• 기타 지역의 위체류 약물전달 시스템(GRDDS) 아웃소싱 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 유형별 : 세계의 위체류 약물전달 시스템(GRDDS) 아웃소싱 시장 성장 기회
  • 투여 형태별 : 세계의 위체류 약물전달 시스템(GRDDS) 아웃소싱 시장 성장 기회
  • 유통 채널별 : 세계의 위체류 약물전달 시스템(GRDDS) 아웃소싱 시장 성장 기회
  • 지역별 : 세계의 위체류 약물전달 시스템(GRDDS) 아웃소싱 시장 성장 기회
• 세계의 위체류 약물전달 시스템(GRDDS) 아웃소싱 시장 최신 동향
• 전략 분석
  • 신제품 개발
  • 세계의 위체류 약물전달 시스템(GRDDS) 아웃소싱 시장 능력 확대
  • 세계의 위체류 약물전달 시스템(GRDDS) 아웃소싱 시장 합병, 인수, 합작투자
  • 인증과 라이선싱

제7장 주요 기업 개요

• F. Hoffmann La Roche
• Glaxo Smith Kline
• Lupin
• Pfizer
• Sun Pharma
• Ranbaxy
• Depomed

영문목차

Gastroretentive Drug Delivery System Outsourcing Trends and Forecast

The future of the global gastroretentive drug delivery system outsourcing market looks promising with opportunities in the high-density system, expandable drug delivery system, bioadhesive drug delivery system, and floating drug delivery system markets. The global gastroretentive drug delivery system outsourcing market is expected to grow with a CAGR of 6.7% from 2024 to 2030. The major drivers for this market are increasing emphasis on patient-centric solutions, rising demand for outsourcing, a growing focus on localized drug delivery, and increasing investments in R&D programs.

• Lucintel forecasts that, within the dosage form category, the capsule is expected to witness the highest growth over the forecast period.
• Within this market, within the type category, the floating drug delivery system is expected to witness the highest growth.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to the region's sophisticated pharmaceutical sector, potent R&D capacities, robust market demand, and well-established healthcare system.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Gastroretentive Drug Delivery System Outsourcing Market

The gastroretentive drug delivery system (GRDDS) market is undergoing significant transformation due to advancements in drug formulation technologies, increasing demand for sustained and controlled-release medications, and the growing trend of outsourcing in the pharmaceutical industry. As GRDDS continues to gain traction, both the drug delivery system market and the outsourcing sector are evolving. Emerging trends such as increased focus on patient-centric formulations, technological innovation, and regulatory shifts are shaping the market landscape.

• Technological Innovations in GRDDS: Innovations in polymer-based systems, pH-sensitive materials, and gastric retention devices are enhancing the performance of GRDDS, making them more effective and patient-friendly.
• Patient-Centric Drug Delivery: There is a growing emphasis on developing GRDDS formulations that cater to individual patient needs, improving drug efficacy and minimizing side effects.
• Growth in Outsourcing Services: As pharmaceutical companies seek to reduce costs and enhance operational efficiency, outsourcing GRDDS manufacturing to specialized contract service providers has been on the rise.
• Focus on Long-Term Medication Adherence: GRDDS, designed for sustained release, is increasingly used for chronic conditions, promoting better adherence to treatment regimens.
• Regulatory Advancements: Evolving regulatory frameworks around the approval and quality control of GRDDS are driving innovation and ensuring greater consistency in the market.

The gastroretentive drug delivery system outsourcing market is set to grow significantly, driven by technological advancements, the increasing demand for patient-specific solutions, and the ongoing trend of outsourcing pharmaceutical manufacturing. Innovations in GRDDS technology, coupled with evolving regulations and a focus on medication adherence, will continue to shape the future of this market. Companies that can leverage these emerging trends will likely see substantial growth and enhanced market share.

Recent Developments in the Gastroretentive Drug Delivery System Outsourcing Market

The GRDDS outsourcing market has witnessed significant recent developments as pharmaceutical companies increasingly recognize the benefits of leveraging specialized contract manufacturers for gastro retentive drug formulations. These developments reflect both technological advancements and a broader trend toward cost-efficient drug development, production, and global market expansion. The market has become more competitive, with firms focusing on innovation and regulatory compliance to meet the needs of a rapidly growing patient base.

• Advances in GRDDS Technology: Recent breakthroughs in GRDDS, such as mucoadhesive systems and bio-adhesive polymers, have improved retention times and drug release control, enhancing therapeutic outcomes.
• Growing Demand for Outsourcing: Pharmaceutical companies are increasingly outsourcing GRDDS manufacturing to reduce production costs, mitigate risks, and shorten time-to-market for new drugs.
• Increase in Regulatory Compliance: Stricter regulatory standards, especially regarding safety and efficacy, are influencing how GRDDS formulations are developed and outsourced, leading to higher-quality systems.
• Expansion of Outsourcing Networks: Leading contract manufacturing organizations (CMOs) have expanded their services globally, catering to pharmaceutical companies looking to tap into emerging markets with robust GRDDS capabilities.
• Enhanced Drug Formulation Capabilities: Companies are enhancing their GRDDS formulations with next-generation technologies like controlled-release mechanisms and targeted delivery, which significantly improve treatment for chronic diseases.

Recent developments in the GRDDS outsourcing market highlight key trends such as technological advancements, increased regulatory scrutiny, and the growing preference for outsourcing as a cost-effective solution. Companies that can innovate and adapt to these changes while maintaining a focus on regulatory compliance and patient outcomes are likely to thrive in this dynamic and rapidly expanding market.

Strategic Growth Opportunities for Gastroretentive Drug Delivery System Outsourcing Market

The GRDDS outsourcing market presents substantial strategic growth opportunities as pharmaceutical companies increasingly focus on developing advanced drug delivery systems for chronic and complex diseases. The benefits of outsourcing, such as cost reduction, accelerated product development, and access to specialized expertise, create a favorable environment for market growth. By leveraging these opportunities, contract manufacturing organizations (CMOs) can expand their capabilities, enhance service offerings, and tap into new markets.

• Expansion of Outsourcing Partnerships: Pharmaceutical companies are increasingly partnering with CMOs that specialize in GRDDS to streamline production processes, improve efficiency, and access cutting-edge technologies.
• Growing Demand for Chronic Disease Management: The rise in chronic conditions such as diabetes, hypertension, and gastrointestinal disorders presents an opportunity to develop specialized GRDDS formulations aimed at improving long-term medication adherence.
• Geographic Expansion: Expanding outsourcing operations into emerging markets with growing healthcare needs can provide CMOs with a significant opportunity to gain market share in new regions.
• Personalized Medicine: The trend toward personalized and patient-specific formulations presents a significant opportunity for GRDDS companies to tailor solutions for individual therapeutic needs.
• Integration of Advanced Technologies: The integration of advanced technologies, such as AI and data analytics, in the GRDDS outsourcing process can optimize product development, reduce costs, and improve quality control.

Strategic growth opportunities in the GRDDS outsourcing market are abundant, driven by the demand for specialized drug delivery systems, advancements in chronic disease management, and the increasing need for personalized medicine. By focusing on expanding outsourcing partnerships, geographic reach, and integrating next-generation technologies, CMOs can capitalize on these opportunities. As the market grows, these factors will help shape the future of GRDDS outsourcing and create new avenues for growth.

Gastroretentive Drug Delivery System Outsourcing Market Driver and Challenges

The GRDDS outsourcing market is influenced by a variety of drivers, such as increasing demand for advanced drug delivery technologies, growing healthcare needs for chronic disease management, and the trend toward cost-efficient pharmaceutical manufacturing. However, the market also faces several challenges, including regulatory complexities, high production costs, and technological limitations. Understanding these drivers and challenges is essential for companies looking to navigate the competitive landscape and capitalize on growth opportunities.

Market Drivers:

• Rising Demand for Chronic Disease Treatments: The increasing prevalence of chronic diseases, such as diabetes and hypertension, drives the need for controlled and sustained drug release, creating demand for GRDDS.
• Outsourcing to Reduce Costs: Pharmaceutical companies are increasingly outsourcing GRDDS manufacturing to reduce production costs, enhance operational flexibility, and speed up time-to-market.
• Technological Advancements in Drug Formulation: Continuous improvements in drug delivery technologies, including bioadhesive systems and controlled-release mechanisms, support the growth of GRDDS applications.
• Focus on Medication Adherence: GRDDS plays a crucial role in improving patient adherence to long-term treatments, thereby driving its adoption in the management of chronic conditions.
• Regulatory Push for Safer, More Effective Therapies: Stricter regulatory requirements for drug delivery systems are driving innovation and enhancing the demand for reliable and compliant GRDDS solutions.

Market Challenges:

• High Development and Manufacturing Costs: The complexity of developing and producing GRDDS formulations can result in high initial investment and operational costs, especially for smaller companies.
• Regulatory Hurdles: Navigating complex and region-specific regulatory requirements can delay market entry and increase development costs.
• Technological Complexity: The need for advanced technologies to design and manufacture GRDDS requires specialized expertise, which may limit market participation for less experienced firms.

The GRDDS outsourcing market is driven by factors such as the increasing demand for chronic disease treatments, technological advancements, and the cost-saving benefits of outsourcing. However, it also faces challenges including high development costs, regulatory complexities, and technological barriers. By overcoming these challenges and leveraging market drivers, companies in the GRDDS outsourcing space can position themselves for sustained growth and success in a rapidly evolving market.

List of Gastroretentive Drug Delivery System Outsourcing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies gastroretentive drug delivery system outsourcing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the gastroretentive drug delivery system outsourcing companies profiled in this report include-

• F. Hoffmann La Roche
• Glaxo Smith Kline
• Lupin
• Pfizer
• Sun Pharma
• Ranbaxy
• Depomed

Gastroretentive Drug Delivery System Outsourcing by Segment

The study includes a forecast for the global gastroretentive drug delivery system outsourcing by type, dosage form, distribution channel, and region.

Gastroretentive Drug Delivery System Outsourcing Market by Type [Analysis by Value from 2018 to 2030]:

• High Density System
• Expandable Drug Delivery System
• Bioadhesive Drug Delivery System
• Floating Drug Delivery System
• Others

Gastroretentive Drug Delivery System Outsourcing Market by Dosage Form [Analysis by Value from 2018 to 2030]:

• Tablets
• Liquid
• Microspheres
• Capsule
• Others

Gastroretentive Drug Delivery System Outsourcing Market by Distribution Channel [Analysis by Value from 2018 to 2030]:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Gastroretentive Drug Delivery System Outsourcing Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Gastroretentive Drug Delivery System Outsourcing Market

Due to the growing need for sustained drug release formulations, the market for outsourcing Gastroretentive Drug Delivery Systems (GRDDS) is progressing significantly. This growth is driven by globalization as pharmaceutical companies enhance patient compliance and optimize therapeutic effectiveness. Outsourcing partners are focusing on innovative technologies and cost-efficient options. MRI's analysis indicates that significant in vitro and in vivo studies, as well as investments from the United States, China, Germany, India, and Japan, are helping develop market-specific novel gastroretentive formulations and manufacturing technologies.

• United States: In the U.S., the GRDDS outsourcing market is seeing an increased level of investment, particularly in offshoring GRDDS through Contract Development and Manufacturing Organizations (CDMOs). Companies are launching sophisticated formulations aimed at improving bioavailability and sustaining the rate of drug release. Collaborating with CDMOs has become a source of innovation for pharmaceutical companies, leading to the development of new types of gastroretentive systems, such as floating tablets and hydrogels, which enhance patient compliance.
• China: The GRDDS market in China is growing rapidly due to the expanding capacity of the domestic pharmaceutical industry and the rising demand for advanced drug delivery strategies. Research projects are being supported by the government, and local companies are taking the initiative to develop the next generation of vertical and lateral GRDDS systems. Domestic and foreign firms are collaborating to improve formulation methods and ensure regulatory compliance.
• Germany: Germany is well-known for its pharmaceutical development and technological advancements, and this is also evident in its GRDDS outsourcing market. Recent trends include the development of individualized therapies and focused drug delivery systems. German CDMOs are increasingly using 3D printing technology to design specific gastroretentive formulations tailored to individual patients.
• India: In India, the GRDDS outsourcing market is expanding as local pharmaceutical companies become more open to innovative approaches in drug delivery. The focus on providing cost-effective healthcare has led to the growth of more affordable GRDDS products. International partnerships are helping Indian companies acquire new competencies, enabling them to establish a global presence.
• Japan: From a regulatory standpoint, Japan's GRDDS outsourcing market is sustained by a strong focus on quality and innovation. Japanese pharmaceutical companies are investing in next-generation formulation technologies and collaborating with research institutes to develop advanced gastroretentive systems. Another emerging trend is the increasing regulatory encouragement for innovative drug delivery products, which is helping bring new products to market more rapidly.

Features of the Global Gastroretentive Drug Delivery System Outsourcing Market

Market Size Estimates: Gastroretentive drug delivery system outsourcing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Gastroretentive drug delivery system outsourcing market size by type, dosage form, distribution channel, and region in terms of value ($B).

Regional Analysis: Gastroretentive drug delivery system outsourcing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, dosage form, distribution channel, and regions for the gastroretentive drug delivery system outsourcing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the gastroretentive drug delivery system outsourcing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the gastroretentive drug delivery system outsourcing market by type (high density system, expandable drug delivery system, bioadhesive drug delivery system, floating drug delivery system, and others), dosage form (tablets, liquid, microspheres, capsule, and others), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Gastroretentive Drug Delivery System Outsourcing Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Gastroretentive Drug Delivery System Outsourcing Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Gastroretentive Drug Delivery System Outsourcing Market by Type
  • 3.3.1: High Density System
  • 3.3.2: Expandable Drug Delivery System
  • 3.3.3: Bioadhesive Drug Delivery System
  • 3.3.4: Floating Drug Delivery System
  • 3.3.5: Others
• 3.4: Global Gastroretentive Drug Delivery System Outsourcing Market by Dosage Form
  • 3.4.1: Tablets
  • 3.4.2: Liquid
  • 3.4.3: Microspheres
  • 3.4.4: Capsule
  • 3.4.5: Others
• 3.5: Global Gastroretentive Drug Delivery System Outsourcing Market by Distribution Channel
  • 3.5.1: Hospital Pharmacies
  • 3.5.2: Retail Pharmacies
  • 3.5.3: Online Pharmacies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Gastroretentive Drug Delivery System Outsourcing Market by Region
• 4.2: North American Gastroretentive Drug Delivery System Outsourcing Market
  • 4.2.1: North American Market by Type: High Density System, Expandable Drug Delivery System, Bioadhesive Drug Delivery System, Floating Drug Delivery System, and Others
  • 4.2.2: North American Market by Dosage Form: Tablets, Liquid, Microspheres, Capsule, and Others
• 4.3: European Gastroretentive Drug Delivery System Outsourcing Market
  • 4.3.1: European Market by Type: High Density System, Expandable Drug Delivery System, Bioadhesive Drug Delivery System, Floating Drug Delivery System, and Others
  • 4.3.2: European Market by Dosage Form: Tablets, Liquid, Microspheres, Capsule, and Others
• 4.4: APAC Gastroretentive Drug Delivery System Outsourcing Market
  • 4.4.1: APAC Market by Type: High Density System, Expandable Drug Delivery System, Bioadhesive Drug Delivery System, Floating Drug Delivery System, and Others
  • 4.4.2: APAC Market by Dosage Form: Tablets, Liquid, Microspheres, Capsule, and Others
• 4.5: ROW Gastroretentive Drug Delivery System Outsourcing Market
  • 4.5.1: ROW Market by Type: High Density System, Expandable Drug Delivery System, Bioadhesive Drug Delivery System, Floating Drug Delivery System, and Others
  • 4.5.2: ROW Market by Dosage Form: Tablets, Liquid, Microspheres, Capsule, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Gastroretentive Drug Delivery System Outsourcing Market by Type
  • 6.1.2: Growth Opportunities for the Global Gastroretentive Drug Delivery System Outsourcing Market by Dosage Form
  • 6.1.3: Growth Opportunities for the Global Gastroretentive Drug Delivery System Outsourcing Market by Distribution Channel
  • 6.1.4: Growth Opportunities for the Global Gastroretentive Drug Delivery System Outsourcing Market by Region
• 6.2: Emerging Trends in the Global Gastroretentive Drug Delivery System Outsourcing Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Gastroretentive Drug Delivery System Outsourcing Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Gastroretentive Drug Delivery System Outsourcing Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: F. Hoffmann La Roche
• 7.2: Glaxo Smith Kline
• 7.3: Lupin
• 7.4: Pfizer
• 7.5: Sun Pharma
• 7.6: Ranbaxy
• 7.7: Depomed